
NYSEHealthcareMedical - Devices
最新数据
US$85.21
+US$0.97 · +1.15%
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
前收盘价
US$85.21
+US$0.97 · +1.15%
盘中时间采用ET。市场数据可能有所延迟。
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
日内区间
当前US$85.21
52周区间
当前US$85.21
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 60.68亿 USD | 54.4亿 USD | 50.1亿 USD | 53.82亿 USD | 52.33亿 USD |
| 销货成本 | 13.27亿 USD | 11.18亿 USD | 10.37亿 USD | 11.67亿 USD | 12.26亿 USD |
| 毛利 | 47.41亿 USD | 43.22亿 USD | 39.73亿 USD | 42.15亿 USD | 40.07亿 USD |
| 研究与开发 | 10.79亿 USD | 10.53亿 USD | 9.63亿 USD | 9.45亿 USD | 9.03亿 USD |
| 销售、一般及管理费用 | 20.85亿 USD | 17.89亿 USD | 15.83亿 USD | 15.68亿 USD | 14.93亿 USD |
| 营业费用 | 31.05亿 USD | 29.43亿 USD | 25.45亿 USD | 25.13亿 USD | 23.96亿 USD |
| 利息收入 | 1.48亿 USD | 1.2亿 USD | 6720万 USD | 3550万 USD | 1740万 USD |
| 利息支出 | — | 1980万 USD | 1760万 USD | 2620万 USD | 2480万 USD |
| 折旧和摊销 | 1.57亿 USD | 1.55亿 USD | 1.45亿 USD | 1.4亿 USD | 1.35亿 USD |
| 营业利润 | 16.36亿 USD | 13.79亿 USD | 14.27亿 USD | 17.02亿 USD | 16.1亿 USD |
| 净利润 | 10.74亿 USD | 41.75亿 USD | 14.02亿 USD | 15.22亿 USD | 15.03亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$101.7
上涨空间 19.35%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2020年6月1日 | 3:1 | — | — |
股票拆分 | 2015年12月14日 | 2:1 | — | — |
股票拆分 | 2010年5月28日 | 2:1 | — | — |
已生效 2020年6月1日
3:1
已生效 2015年12月14日
2:1
已生效 2010年5月28日
2:1
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T939.92亿0.07%129.35万亿 JPY0.09%JP¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI16.61亿0.07%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO13.88亿0.08%1.8万亿 USD0.03%US$715.59+0.61%
Vanguard Morningstar Mid-Cap ETFVO11.3亿0.50%2264亿 USD0.03%US$81.14+0.92%
iShares Core S&P 500 ETFIVV6.46亿0.07%8964.4亿 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY5.94亿0.07%8172亿 USD0.09%US$778.57+0.60%
Vanguard Morningstar Value ETFVTV4.99亿0.19%2624亿 USD0.03%US$220.59+0.44%
Vanguard Morningstar Mid-Cap Growth ETFVOT4.01亿1.17%341亿 USD0.05%US$302.48+1.55%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
Vanguard Morningstar Mid-Cap Growth ETFVOTAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。